Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment

J X Zou; J Braun; J Sieper

Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment

Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S34-7.

Authors

J X Zou¹, J Braun, J Sieper

Affiliation

¹ Department of Rheumatology, Klinikum Benjamin Franklin, Free University, Berlin, Germany.

PMID: 12463444

Abstract

TNFalpha is expressed in high amounts at the site of inflammation in ankylosing spondylitis, which provided the basis to initiate treatment studies with TNF-blocking agents. We could show that the immunological effects of infliximab and etanercept differ in patients with AS, although the clinical effect was similarly good. While infliximab induced a downregulation of the production of the T-helper 1-cytokines IFNgamma and TNFalpha, etanercept treatment triggered rather an upregulation of these cytokines secreted by T cells after in vitro stimulation.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use*
Antirheumatic Agents / therapeutic use*
Down-Regulation
Etanercept
Humans
Immunoglobulin G / therapeutic use*
Infliximab
Interferon-gamma / metabolism
Receptors, Tumor Necrosis Factor / therapeutic use*
Spondylitis, Ankylosing / drug therapy*
Spondylitis, Ankylosing / immunology*
Spondylitis, Ankylosing / physiopathology
Treatment Outcome
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Tumor Necrosis Factor-alpha / metabolism
Up-Regulation

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Interferon-gamma
Infliximab
Etanercept